Xcout Intel
Protagenic Therapeutics, Inc.new
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Subscribe to see Protagenic Therapeutics, Inc.new’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Protagenic Therapeutics, Inc.new at a glance
Protagenic Therapeutics, Inc.new is a biotech company headquartered in New York, United States. It is publicly listed (PTIX) with a market capitalisation of $391,005. Xcout tracks 16 named people at Protagenic Therapeutics, Inc.new, including William Nichols Jr. (President).
Protagenic Therapeutics, Inc.new leadership
- William Nichols Jr.President
- Andrew SleeChief Development Officer
- Robert Benjamin SteinChief Medical Officer
- Garo H. ArmenExecutive Chairman
- Barrett EvansDirector
- Brian CorveseDirector
10 more named people on record for Protagenic Therapeutics, Inc.new, with roles, board committees and tenure — see the full roster →
Protagenic Therapeutics, Inc.new competitors
A few of Protagenic Therapeutics, Inc.new's closest competitors — see the full list of competitors and alternatives →
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company headquartered at the Pacific Research Center in Newark, California, focused on peptide drug discovery.
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
AtaiBeckley Inc. has its corporate headquarters located in New York, USA. The biopharmaceutical company is on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments.
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Get Protagenic Therapeutics, Inc.new's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Protagenic Therapeutics, Inc.new in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access